Design of next generation antibody drug conjugates

Yaoxue Xuebao

Volumn 48, Issue 7, 2013, Pages 1053-1070

  Zhu, Gui Dong ^a,c   Fu, Yang Xin ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

^c Yao Yuan Academy for Pharma Innovation   (United States)

Author keywords

Antibody; Antibody drug conjugate; Linker; Payload

Indexed keywords

ANTITUMOR ANTIBODY DRUG CONJUGATE; CANCER ANTIBODY; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AMINOBENZOIC ACID DERIVATIVE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; AURISTATIN; CYTOTOXIN; MAYTANSINE; OLIGOPEPTIDE;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; BINDING AFFINITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG PROTEIN BINDING; REVIEW; TARGET CELL; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; NEOPLASMS; PATHOLOGY;

AMINOBENZOATES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CYTOTOXINS; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; NEOPLASMS; OLIGOPEPTIDES;

EID: 84883622138     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. http://yypharm.cn/news/yibanxinwen/2013-03-09/409.html.
2. http://yypharm.cn/news/kzll/2013-02-23/377.html.
3. Verma S, Miles D, Gianni L, et al. Trastuzumab entansine for HER2-positive advanced breast cancer [J]. N Engl J Med, 2012, 367: 1783-1791.
4. Perkel JM. Armed antibodies readied for war on cancer [R]. Fierce Biotech Special Report, 2012, (4-92512-2).
5. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components [J]. Toxins (Basel), 2011, 3: 848-883
6. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies [J]. Bioconjug Chem, 2010, 21: 5-13.
7. Senter PD. Potent antibody drug conjugates for cancer therapy [J]. Curr Opin Chem Biol, 2009, 13: 235-244.
8. Sapra P, Hooper AT, O'Donnell CJ, et al. Investigational antibody drug conjugates for solid tumors [J]. Expert Opion Investig Drug, 2011, 20: 1131-1149.
9. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy [J]. Ann Rev Med, 2012, 64: 15-29.
10. Ducry L. Challenges in the development and manufacturing of antibody-drug conjugates [J]. Methods Mol Biol, 2012, 899: 489-497.
11. Adair JR, Howard PW, Hartley JA, et al. Antibody drug conjugates - a perfect synergy [J]. Expert Opin Biol Ther, 2012, 12: 1191-1206.
12. Lin L, Ding Q, Tang C, et al. Development of antibody drugs targeting against HER2 for cancer therapy [J]. Acta Pharm Sin 2012, 47: 1287-1296.
13. Mathé G, Loc TB, Bernhard J. Effet sur la leuc émie 1210 de la souris d'une combinaison par diazotation d'A-méthopérine et de γ-globulines de hamsters porteurs de cette leuc émie par hétérogreffe [J]. CR Hebd Seances Acad Sci, 1958, 246: 1626-1628.
14. Rowland GF, O'Neill GJ, Davies DA. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage [J]. Nature, 1975, 255: 487-488.
15. Miao QF, Shao RG, Zeng YS. An overview of antibody-based cancer therapy [J]. Acta Pharm Sin 2012, 47: 1261-1268.
16. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity [J]. Bioconjug Chem, 2006, 17: 114-124. (Pubitemid 43157592)
17. Widdison WC, Wilhelm SD, Cavangh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer [J]. J Med Chem, 2006, 49: 4392-4408. (Pubitemid 44036683)
18. Lambert JM. Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer [J]. Drugs Future, 2010, 35: 471-480.
19. Wang Y, Han YX, Jiang JD. Progress in calicheamicins [J]. Chin J New Drugs 2007, 16: 1341-1345.
20. Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents [J]. Expert Opin Investig Drugs, 2011, 20: 733-744.
21. Beusker PH, Coumans RGE, Elgersma RC, et al. Novel conjugates of CC-1065 analogs and bifunctional linkers: WO2011133039A2 [P]. 2011-10-27.
22. Beusker PH, Spijker HJ, Joosten JAF, et al. Preparation of substituted CC-1065 analogs and their conjugates for treating tumors: WO2009017394A1 [P]. 2009-02-05.
23. Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen specific in vitro anticancer activity [J]. Bioconjug Chem, 2002, 13: 855-869. (Pubitemid 34801129)
24. Hamann PR, Hirunan LM, Beyer CF, et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts [J]. Bioconjug Chem, 2005, 16: 354-360. (Pubitemid 40388211)
25. Ojima I, Geng X, Wu X, et al. Tumor-specific novel taxoidmonoclonal antibody conjugate [J]. J Med Chem, 2002, 45: 5620-5623. (Pubitemid 35453753)
26. Xie H, Audette C, Hoffee M, et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice [J]. J Pharmacol Exp Ther, 2004, 308: 1073-1082. (Pubitemid 38263984)
27. Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates [J]. Bioconjug Chem, 2008, 19: 358-361. (Pubitemid 351213870)
28. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence [J]. Cancer, 2005, 104: 1442-1452. (Pubitemid 41356159)
29. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J]. Nat Biotechnol, 2003, 21: 778-784. (Pubitemid 36791396)
30. Bartlett N, Forero-Torres A, Rosenblatt J, et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-dug conjugate (ADC) targeting CD30, in phase 1 dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) [J]. J Clin Oncol, 2009, 27: 8500.
31. Ducry L, Stump B, Wong W, et al. Branched linker for protein drug conjugates: WO 113847 [P]. 2012-08-30.
32. Jeffrey SC, Andreyka JB, Bernhardt SX, et al. Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates [J]. Bioconjug Chem, 2006, 17: 831-840. (Pubitemid 43794395)
33. Jeffrey SC, De Brabander J, Miyamoto J, et al. Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents [J]. ACS Med Chem Lett, 2010, 1: 277-280.
34. http://www.aglaia-biomedical.com/specific-news.php?id=21.
35. http://www.drugs.com/clinical-trials/syntarga-demonstrates-vivo-proof- concept-antibody-conjugate-technology-6583.html.
36. Chari RVG. Targeted cancer therapy: conferring specificity to cytotoxic drugs [J]. Acc Chem Res, 2008, 41: 98-107.
37. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin 's lymphoma: target and linker-drug selection [J]. Cancer Res, 2009, 69: 2358-2364.
38. Vogel CL, Burris HA, Limentani S, et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results [J]. J Clin Oncol, 2009, 27: 1017.
39. Alley SC, Benjamin DR, Jeffrey SC, et al. Contribution of linker stability to the activities of anticancer ¡munoconjugates [J]. Bioconjug Chem, 2008, 19: 759-765. (Pubitemid 351431408)
40. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing [J]. Cancer Res, 2006, 66: 4426-4433.
41. Bernardes GJL, Casi G, Trussel S, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy [J]. Angew Chem Int Ed Engl, 2012, 51: 941-944.
42. Steiner M, Hartmann I, Perrino E, et al. Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature [J]. Chem Sci, 2013, 4: 297-302.
43. + T cells [J]. Clin Cancer Res, 2013, 19: 1476-1486.
44. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity [J]. Cancer Cell, 2010, 18: 160-170.
45. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance [J]. Adv Drug Deliv Rev, 2008, 60: 1421-1434.
46. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001, 344: 783-792. (Pubitemid 32222155)
47. Zhang Y, He JS, Hong T. Advances and application of recombinant antibody drugs [J]. China Biotechnol 2009, 29: 102-106.
48. Lian GY, Yu B. Chemical glycosylation of protein [J]. Sci Sin Chim 2012, 42: 1746-1759.
49. http://www.biosimilarnews.com/a-biobetter-trastuzumab-is-on-the-way.
50. Metz S, Haas AK, Daub K, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery [J]. Proc Natl Acad Sci USA, 2011, 108: 8194-8199.
51. Hussain AF, Kampmeier F, von Feibert V, et al. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells [J]. Bioconjug Chem, 2011, 22: 2487-2495.
52. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate [J]. Clin Cancer Res, 2004, 10: 7063-7070. (Pubitemid 39383058)
53. McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometrics of drug attachment [J]. Protein Eng Des Sel, 2006, 19: 299-307. (Pubitemid 43999640)
54. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index [J]. Nat Biotechnol, 2008, 26: 925-932.
55. Hutchins BM, Kazane SA, Staflin K, et al. Selective formation of covalent protein heterodimers with an unnatural amino acid [J]. Chem Biol, 2011, 18: 299-303.
56. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates [J]. Science, 1993, 261: 212-215. (Pubitemid 23265398)
57. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors [J]. J Clin Oncol, 2000, 18: 2282-2292. (Pubitemid 30350221)
58. DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma [J]. Clin Cancer Res, 2006, 12: 242-249. (Pubitemid 43166200)
59. http://www.yypharm.cn/news/sskt/2013-05-23/439.html.
60. http://clinicaltrials.gov/ct2/show/NCT00562965.
61. King HD, Dubowchik GM, Mastalerz H, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyl-eneglycol chains [J]. J Med Chem, 2002, 45: 4336-4343. (Pubitemid 35025579)
62. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia [J]. Bioconjug Chem, 2002, 13:47-58. (Pubitemid 34119634)
63. Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells [J]. Mol Cancer Ther, 2007, 6: 3009-3018. (Pubitemid 350206779)
64. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates [J]. Clin Cancer Res, 2004, 10: 7842-7851. (Pubitemid 39587522)
65. Erickson HK, Phillips GD, Leipold DD, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates [J]. Mol Cancer Ther, 2012, 11: 1133-1142.
66. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [J]. J Clin Oncol, 2013, 31: 1157-1163.
67. http://www.globenewswire.com/news-release/2013/02/14/523727/10021886/en/ Progenics-Pharmaceuticals-Presents-Updated-Data-From-Phase-1-Study-of-PSMA-ADC. html.
68. Mullard A. Maturing antibody-drug conjugate pipeline hits 30 [J]. Nat Rev Drug Discov, 2013, 12: 329-333.
69. Zolot RS, Basu S, Million RP. Antibody-drug conjugate [J]. Nat Rev Drug Discov, 2013, 12: 259-260.